At the stock markets, the S&P BSE Sensex surged 848 points, or 1.74%, to close at 49,581 on Monday, May 17, 2021. The Nifty 50 index jumped 245 points, or 1.7 per cent, to 14,923. In the broader market, the BSE Mid-cap and the Small-cap index jumped 1.6 per cent, each. But certain stocks came in the news after the market was closed. These stocks can impact the indices, when it reopens on Monday, May 17, 2021. List of such five stocks:

COMMERCIAL BREAK
SCROLL TO CONTINUE READING

See Zee Business Live TV Streaming Below:

Bharti Airtel: Telecom major Bharti Airtel has reported an 11.1% QoQ decline in consolidated profit at Rs 759 crore for the quarter ended March 31, 2021. It had posted a profit of Rs 854 crore in the previous quarter ended December 31, 2021. Consolidated revenue dropped 2.90% to Rs 25,747 crore as against Rs 26,518 crore posted in the previous quarter. EBITDA stood at Rs 12,583 crore, up 3.3% from Rs 12,178 crore. The margin improved to 48.9% in Q4FY21 as against 45.9% posted in Q4FY20. ARPU dropped 12.7% in the quarter to Rs 145 against Rs 166 of the previous quarter. 

Gland Pharma + GNFC + MRPL + Orient Cement

Gland Pharma: The pharmaceutical company has reported a 33.7% YoY rise in the consolidated profit at Rs 260.4 crore for the quarter ended March 31, 2021. It had posted a profit of Rs 194.8 crore in the same quarter of the previous financial year. Consolidated revenue from operations grew 39.8% to Rs 887.8 crore in the reported quarter as against Rs 635.3 crore posted last year. EBITDA stood at Rs 327.7 crore up 36.7% from Rs 239.8 crore posted last year. Margin fell to 36.9% in Q4FY21 as against 37.8% posted in Q4FY20.

GNFC: The chemical company on Monday reported a 29.4% YoY rise in the consolidated profit at Rs 310.5 crore for the quarter ended March 31, 2021. It had posted a profit of Rs 240 crore in the same quarter of the previous financial year. Consolidated revenue from operations grew 29.1% to Rs 1,733 crore as compared to Rs 1,342.5 crore posted last year. EBITDA stood at Rs 470.4 crore, up 189.11%, against Rs 162.7 crore posted last year. Margin improved to 27.1% in Q4FY21 as against Rs 12.1% posted in Q4FY20. MRPL: The oil refilling company has reported a consolidated profit of Rs 268.7 crore for the quarter ended March 31, 2021, against a consolidated loss of Rs 264.7 crore posted in the previous quarter ended December 31, 2021. Consolidated revenue from operations grew 72.5% at Rs 13,615.5 crore in the reported quarter against Rs 7,893.2 crore posted in the December quarter. EBITDA stood at Rs 905.5 crore, up 17.6 times from Rs 51.6 crore posted last year. Margin improved to 6.7% in Q4FY21 as compared to 0.7% posted in Q3FY21. GRM stood at 6.50 $/barrel. 

Orient Cement: (NAKK stock) The Cement manufacturer has reported a 126.5% YoY to Rs 99.9 crore for the quarter ended March 31, 2021. It had posted a profit of Rs 44.1 crore in the same quarter of the previous financial year. Consolidated revenue rose 27.1% to Rs 831.6 crore as against Rs 654.5 crore posted last year. EBITDA stood at Rs 202.6 crore, up 62.5%, against Rs 124.7 crore posted last year. Margin improved to 24.4% in Q4FY21 as against 19.1% posted in Q4FY20. The board has recommended a final dividend of Rs 1.50/share. Net debt reduction of Rs 450 Crores in FY’21. 

Union Bank: (CMP: 37.90) State-owned Union Bank of India (UBI) on Monday said it has approved raising of Rs 1,750 crore through qualified institutional placement (QIP). The committee has set the floor price of the QIP at Rs 35.60 per equity share. The bank may offer a discount of not more than 5 per cent on the floor price so calculated for the issue, it added. The board will meet on May 20, 2021, to take a decision on the final price. 

Panacea Biotec + PVR

Panacea Biotec: Serum Institute of India CEO Adar Poonawalla on Monday offloaded his entire stake in Panacea Biotec amounting to 5.15 per cent shareholding of the firm for Rs 118 crore, through an open market transaction. The shares were picked by the Serum Institute of India (SII). Poonawalla sold 31.57 crore scrips he held in the firm at a price of Rs 373.85 per share. The shares were bought by SII at the same price, through a separate transaction. Serum now holds 10% in Panacea Biotech. 
PVR: BOFA Securities Europe Bought 3.49 Lakh Shares @ Rs 1169/ Share 

COVID Impact: RBI has released its report on the functioning of the NBFCs in the second and third quarter of the financial year 2020-21 during the CORONA period. In its report, RBI has said that the growth of NBFCs decreased based on the consolidated balance sheet and more impact was seen on the NBFCs lending to industrialists, especially MSMEs. The report says that the performance of NBFCs engaged in the retail loan segment has improved due to fewer defaults. There was a slight increase in profits in the second and third quarter of FY21 due to a decline in expenses as compared to income. Due to regulatory measures, the asset quality has been better than the last year.